Clinical Trial Update: Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial comparing liposomal doxorubicin plus gemcitabine to oxaliplatin plus fluorouracil/leucovorin for hepatocellular carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• OXALIPLATIN (Oxaliplatin)
• fluorouracil/leucovorin (5-FU/leucovorin)
• liposomal doxorubicin (doxorubicin liposomal)

Snippet

Sponsor: Guangxi Medical University | Conditions: Hepatocellular Carcinoma | Phase 2, Phase 3 | Status: WITHDRAWN